BGLAP and chronic kidney disease: Losartan treatment had no impact on the extent of vascular calcification as shown by von Kossa staining (Figures 2C,E) and de novo expression of osteocalcin in calcified areas was increased to a similar level as in CKD-MBD rats (Figures 2G,H,J).